nach oben

Drugs

Erschienen in:

01.09.2000 | Adis New Drug Profile

Nateglinide

A Viewpoint by Riccardo Perfetti

verfasst von: Riccardo Perfetti

Erschienen in: Drugs | Ausgabe 3/2000

Einloggen, um Zugang zu erhalten

Excerpt

The onset of type 2 diabetes is characterised by 2 determining factors: insufficient ability to secrete insulin and/or resistance to its biological action.[1] Current biomedical research continues to clarify the relative contributions of these defects to the pathogenesis of type 2 diabetes, and novel pharmacological agents are designed specifically to correct either the impaired insulin secretory activity or the resistance to the action of insulin. …

Polonsky KS. Evolution of beta-cell dysfunction in impaired glucose tolerance and diabetes. Exp Clin Endocrinol Diabetes 1999; 107 Suppl. 4: S124–7PubMedCrossRef

Kikuchi M. Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166. Diabetic Med 1996; 13 Suppl. 6: S151–5PubMed

Akiyoshi M, Kakei M, Nakazaki M. A new hypoglycemic agent, A-4166, inhibits ATP-sensitive potassium channels in rat pancreatic β-cells. Am J Physiol 1995; 268 (2 pt 1): E185–93PubMed

Ikenoue T, Okazaki K, Fujitani S, et al. Effect of a new hypoglycemic agent, A-4166 [(-)-N-(trans-4-isopropylcyclo-hexanecarbonyl)-D-phenylalanine], on postprandial blood glucose excursion: comparison with voglibose and gliben-clamide. Biol Pharm Bull 1997; 20(4): 354–9PubMedCrossRef

Ikenoue T, Akiyoshi M, Fujitani S, et al. Hypoglycaemic and insulinotropic effects of a novel oral antidiabetic agent, (-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine (A-4166). BrJPharmacol 1997; 120: 137–45

Sato Y, Nishikawa M, Shinkai H, et al. Possibility of ideal blood glucose control by a new oral hypoglycaemic agent, N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanine (A-4166), and its stimulatory effect on insulin secretion in animals. Diabetes Res Clin Pract 1991; 12(1): 53–9PubMedCrossRef

Kalbag J, Hirschberg Y, McLeod JE Comparison of mealtime glucose regulation by nateglinide and repaglinide in healthy subjects [abstract]. Diabetes 1999 May; 48 Suppl. 1: A106CrossRef

Bloomgarden ZT. New and traditional treatment of glycemia in NIDDM. Diabetes Care 1996; 19(3): 295–9PubMed

Hirschberg Y, McLeod J, Garreffa S. Pharmacodynamics and dose response of nateglinide in type 2 diabetics [abstract]. Diabetes 1999 May; 48 Suppl. 1: A100

Titel: Nateglinide
A Viewpoint by Riccardo Perfetti
verfasst von: Riccardo Perfetti
Publikationsdatum: 01.09.2000
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 3/2000
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200060030-00008

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2000

Immune Tolerance Therapy for Haemophilia

Potential of Substance P Antagonists as Antiemetics

Nateglinide

Oral versus Topical NSAIDs in Rheumatic Diseases

Combination Chemotherapy for Hepatitis B Virus

Desirudin